Eltrombopag

Cancer Treatment and Research

Volumn 157, Issue , 2011, Pages 289-303

  Bussel, James B ^a   Pinheiro, Mariana P ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DANAZOL; ELTROMBOPAG; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; STAT PROTEIN; THROMBOPOIETIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CATARACT; CD34 SELECTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER CIRRHOSIS; LIVER FUNCTION; NAUSEA; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPLENECTOMY; STRUCTURE ANALYSIS; THROMBOCYTE COUNT; XEROSTOMIA;

ANIMALS; BENZOIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDRAZINES; MICE; NEOPLASMS; PYRAZOLES; THROMBOCYTOPENIA;

EID: 78349268297     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7073-2_17     Document Type: Review

References (8)

1. Erickson-Miller C, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27:424-30.
2. Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In: Metcalf BW, Dillon S, editors. Target validation in drug discovery. Burlington, MA: Academic Press; 2007. pp. 241-254.
3. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739-41.
4. Bussel JB, et al. Eltrombopag for the treatment of Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-47.
5. Bussel JB, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;373:641-8.
6. McHutchinson JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227-36.
7. Cheng G, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, phase 3 study. Lancet, 2010, in press.
8. EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP) - EXTEND STUDY.